Business
Director/PDMR Shareholding
Venture Life Group PLC announced that Chief Executive Officer Jerry Randall sold 387,705 ordinary shares at a volume-weighted average price of 66.22 pence per share, totaling approximately £256,600. This sale was to cover the exercise price of options and resulting tax liabilities, following his exercise of options for 483,333 shares. After this transaction, Mr. Randall beneficially holds 2,348,828 ordinary shares, representing 1.82% of the company's issued share capital. Disclaimer*

About this update from Venture Life Group Plc
9 January 2026 VENTURE LIFE GROUP PLC ("Venture Life", "VLG" or the "Company") Director/PDMR Shareholding Further to the announcement on 2 January 2026 of the exercise of options over 483,333 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") by Jerry Randall (Chief Executive Officer), the Company has been notified that, in order to satisfy the payment of the exercise price of the options and the personal tax liabilities resulting from the exercise of the options, Jerry Randall has sold 387,705 Ordinary Shares at a volume-weighted average price of 66.22 pence per Ordinary Share ("the "Share Sale"). Following the Share Sale, Jerry Randall beneficially holds 2,348,828 Ordinary Shares representing approximately 1.82 per cent. of the Company's issued share capital. For further information, please contact: Venture Life Group PLC +44 (0) 1344 578004 Jerry Randall, Chief Executive Officer Daniel Wells, Chief Financial Officer Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500 Stephen Keys/George Lawson (Corporate Finance) Michael Johnson (Sales) About Venture Life ( www.venture-life.com ) Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. The Company makes the following disclosure in accordance with article 19(3) of the Market Abuse Regulation: 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Jerry Randall 2 Reason for the notification a) Position/status Chief Executive Officer b) Initial notification /Amendment Initial notification 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Venture Life Group plc b) LEI 213800S8CZUPLAB2KC70 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Ordinary Shares of 0.3p each in Venture Life Group plc GB00BFPM8908 b) Nature of the transaction Sale of Ordinary Shares c) Price(s) and volume(s) Price Volume 66.50 pence 66.50 pence 66.90 pence 66.00 pence 66.00 pence 100,000 54,690 10,000 50,000 173,015 d) Aggregated information - Aggregated volume - Price - 387,705 Ordinary Shares - 66.22 pence e) Date of the transaction 7 / 8 / 9 January 2026 f) Place of the transaction London Stock Exchange
View stock analysis, news, and events for Venture Life Group Plc